A special episode focused on the AbbVie-commissioned survey, revealing firm support for increased investment in medicines and the true extent of patients paying the cost of their prescriptions. What does it mean and what is the opportunity?

Another order on pharmaceutical pricing, but what does it mean? What does the Government's productivity roundtable have in common with the HTA Review? Screening programs that aren't, and a co-payment reduction that puts the safety net further o...

A sense of entitlement that needs to be questioned, Australia is on the list of nine countries to be targeted over pharmaceutical pricing, and the hopeless hypocrisy of allowing a group of disreputable regimes to have a say on this country's re...

The opportunity for Australia is to do less deflecting on healthcare affordability and engage in an honest discussion about the genuine challenges confronting many Australians. The debate does not just deflect on affordability.

The ongoing debate regarding the US, the Trump administration's potential tariffs on pharmaceuticals and the PBS is mainly characterised by falsehoods and errors. We discuss our incredible frustration over a debate that is almost entirely disco...